Risk and timing of isotretinoin‐related laboratory disturbances: a population‐based study
International Journal of Dermatology · 2024
DOI: 10.1111/ijd.17225 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Shirin Emtenani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany. Hauptthemen laut MEDLINE: Isotretinoin, Acne Vulgaris, Dermatologic Agents, Aspartate Aminotransferases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Uncertainty surrounds the optimal routine laboratory monitoring in acne patients treated with isotretinoin.
Objective
Our aim was to evaluate the risk of mild and severe laboratory abnormalities in patients with acne starting isotretinoin versus oral antibiotic treatment.
Methods
A global population‐based retrospective cohort study assigned two groups of patients with acne‐prescribed isotretinoin ( n = 79,012) and oral antibiotics ( n = 79,012). Comprehensive propensity‐score matching was conducted.
Results
Compared to acne patients treated with oral antibiotics, those under isotretinoin demonstrated an increased risk of grade ≥3 hypertriglyceridemia (hazard ratio [HR], 7.85; 95% confidence interval [CI], 5.58–11.05; P < 0.001) and grade ≥3 elevated aspartate transaminase (AST) levels (HR, 1.45; 95% CI, 1.13–1.85; P = 0.003) within the initial 3 months of treatment. The absolute risk of these abnormalities among isotretinoin initiators was 0.4% and 0.2%, respectively. The risk difference of these findings was clinically marginal: 3 and 1 additional cases per 1,000 patients starting isotretinoin, respectively. There was no significant risk of grade ≥3 impairment in cholesterol, alanine transaminase, gamma‐glutamyl transferase, or creatinine levels under isotretinoin. Most laboratory abnormalities were documented 1–3 months after drug initiation in time‐stratified analysis.
Conclusion
Isotretinoin is associated with a clinically marginal increased risk of severe hypertriglyceridemia and hypertransaminasemia. Routine blood testing should be performed 1–3 months after commencing therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
- School of Medicine, Royal College of Surgeons in Ireland, Manama, Bahrain.
- Department of Dermatology, University Hospital of Schleswig Holstein (UKSH), Campus Lübeck, Lübeck, Germany.
ORCID-Profile: Mariam Abdelghaffar, Khalaf Kridin
Zitieren
APA
Emtenani, S., Abdelghaffar, M., Ludwig, R. J., Schmidt, E., & Kridin, K. (2024). Risk and timing of isotretinoin‐related laboratory disturbances: a population‐based study. International Journal of Dermatology. https://doi.org/10.1111/ijd.17225
Vancouver
Emtenani S, Abdelghaffar M, Ludwig RJ, Schmidt E, Kridin K. Risk and timing of isotretinoin‐related laboratory disturbances: a population‐based study. International Journal of Dermatology. 2024. doi:10.1111/ijd.17225
BibTeX
@article{Emtenani2024,
author = {Emtenani, Shirin and Abdelghaffar, Mariam and Ludwig, Ralf J and Schmidt, Enno and Kridin, Khalaf},
title = {Risk and timing of isotretinoin‐related laboratory disturbances: a population‐based study},
journal = {International Journal of Dermatology},
year = {2024},
doi = {10.1111/ijd.17225}
}
EUVIMED